Dear Editor,
We carefully read the comments [1] on our study [2]. The fact that our paper had such an impact (more than 2,500 citations in Google Scholar) testifies that it met an important expectation. In order to be able to give an element of reflection for COVID-19 therapeutics, we have chosen as endpoint the viral clearance assessed by PCR in the nasopharynx. Indeed, this marker has become necessary for the management of bacterial and viral infections, as in the cases of HIV infection or hepatitis C. Chinese authors reported in March 2020 that the median duration of viral carriage in the nasopharynx was 20 days and that the longest carriage lasted 37 days [3]. Hence, we initially submitted a project that included the analysis of a single arm, using hydroxychloroquine (HCQ), to determine if we could have a shortening of the duration of viral carriage in our patients compared to this Chinese work. Fortunately, we had to test and follow up patients who had been hospitalized in other centers and who did not receive this treatment, which allowed comparison. The results were interpreted by the laboratories that performed the tests. In our laboratory, PCR were determined to be positive in case of Ct values lower than 35, which we were able to confirm in the largest study published to date that compared culture and PCR [4]. Since then, we have performed >250,000 PCRs in our laboratory, diagnosed >13,000 people, and the efficacy of HCQ on viral carriage, which was the only element we reported in our seminal article, has been confirmed in a larger set of patients by our team [5] as well as by others [6]. Studies and meta-analyses are consistent regarding the fact that this treatment shortens the duration of viral carriage. Finally, the importance of this preliminary paper was underlined by the fact that numerous international publications have now been produced on HCQ that evaluated its effect, either on virus disappearance or on death. In total, it is important to keep in mind that during emerging epidemics with unknown viruses, preliminary data are essential to allow the choice of therapeutic strategies when no treatment has been validated. The need for information in real-time in such context is also illustrated by the burst of pre-print publications during this SARS-CoV-2 pandemic.
Declaration of Competing Interest
The authors declare no competing interests.
Acknowledgments
Funding
No funding sources.
Ethical approval
Not applicable.
Footnotes
This article refers to 10.1016/j.ijantimicag.2020.105949 and 10.1016/j.ijantimicag.2020.106170
References
- 1.El Bakkouri K. Hydroxychloroquine (HCQ): real treatment or false hope? Int J Antimicrob Agents. 2021 doi: 10.1016/j.ijantimicag.2020.106170. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Gautret P., Lagier J.C., Parola P., Hoang V.T., Meddeb L., Mailhe M. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56 doi: 10.1016/j.ijantimicag.2020.105949. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
- 3.Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–1062. doi: 10.1016/S0140-6736(20)30566-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Jaafar R., Aherfi S., Wurtz N., Grimaldier C., Hoang V.T., Colson P. Correlation between 3790 qPCR positives samples and positive cell cultures including 1941 SARS-CoV-2 isolates. Clin Infect Dis. 2020 Sep 28 doi: 10.1093/cid/ciaa1491. ciaa1491Online ahead of print. [DOI] [Google Scholar]
- 5.Lagier J.C., Million M., Gautret P., Colson P., Cortaredona S., Giraud-Gatineau A. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis. Travel Med Infect Dis. 2020;36 doi: 10.1016/j.tmaid.2020.101791. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Million M., Roussel Y., Gautret P., Raoult D., Response to IJAA-D-20-00393 Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis. Int J Antimicrob Agents. 2021;57(1) doi: 10.1016/j.ijantimicag.2020.106240. [DOI] [PMC free article] [PubMed] [Google Scholar]